GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Clovis Oncology Inc (CLVS) [hlAlert]

Rating:
Buy CLVS
up 86.60 %

Clovis Oncology Inc (CLVS) rated Buy with price target $90 by Stifel

Posted on: Thursday,  Feb 26, 2015  8:25 AM ET by Stifel

Stifel rated Buy Clovis Oncology Inc (NASDAQ: CLVS) on 02/26/2015. Previously Stifel rated Buy Clovis Oncology Inc (NASDAQ: CLVS) on 06/05/2014.,
when the stock price was $40.77. Since then, Clovis Oncology Inc has gained 86.61% as of 01/20/2016's recent price of $76.08.
If you would have followed the previous Stifel's recommendation on CLVS, you would have gained 86.6% of your investment in 594 days.

Clovis Oncology, Inc. (Clovis) is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor.

Stifel
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/26/2015 8:25 AM Buy
None
74.15 90.00
as of 8/27/2015
1 Week down  -5.53 %
1 Month down  -13.85 %
3 Months down  -24.22 %
1 YTD up  2.60 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/7/2014 9:25 AM Buy
None
57.42 75.00
6/5/2014 12:00 AM Buy
None
40.77 50.00
9/6/2013 8:25 AM Hold
None
63.75

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy